L3VLUP
ProSign in

ALEC in the 13F filings

Alector Inc · CUSIP 014442107

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021
Quarter end
31 Dec 2021
the date the book describes
Filed
14 Feb 2022
latest of these filings; the earliest 20 Jan 2022
Managers listing it
3
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q3 2021 and Q4 2021; 2 listed it in both
Shares listed
1,496,970
combined, among listed positions
Reported value
$31m
combined, at the quarter end

Managers listing ALEC in Q4 2021

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q3 2021, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

3 of 3 holders

ActionFiling
Marshall Wace LLP1,080,854$22munder 0.1%Addedn.a.14 Feb 2022 (the filing on sec.gov)
Baillie Gifford & Co359,724$7.4munder 0.1%Added+19,37220 Jan 2022 (the filing on sec.gov)
PDT Partners LLC56,392$1.2m0.09%Trimmed-45,67114 Feb 2022 (the filing on sec.gov)

Largest increases and reductions, by shares

Q3 2021 to Q4 2021, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
2 in Q4 2022 to 1 in Q3 2024

Tracked managers listing it, at least.

01234201920202021202220232024
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
ALEC by quarter
QuarterHoldersReported valueBuyersSellers
Q1 20191$41kn.a.n.a.
Q2 20191$42kn.a.n.a.
Q3 20191$30kn.a.n.a.
Q4 20191$36kn.a.n.a.
Q1 20202$9.7mn.a.n.a.
Q2 20204$16mn.a.n.a.
Q3 20203$3.2mn.a.n.a.
Q4 20202$4.0mn.a.n.a.
Q1 20212$7.2mn.a.n.a.
Q2 20212$8.2mn.a.n.a.
Q3 20213$20mn.a.n.a.
Q4 20213$31mn.a.n.a.
Q1 20221$5.6mn.a.n.a.
Q2 20221$3.6mn.a.n.a.
Q3 20221$3.5mn.a.n.a.
Q4 20222$4.1mn.a.n.a.
Q1 20232$2.9mn.a.n.a.
Q2 20233$2.9mn.a.n.a.
Q3 20231$2.4mn.a.n.a.
Q4 20232$2.9m11
Q1 20244$11m21
Q2 20242$1.3m11
Q3 20241$367k01

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

ALEC and GILD →ALEC and AMGN →ALEC and ARGX →Choose a stock to compare with ALEC →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own ALEC, latest filings →Back to the 13F Explorer →